Biotech M&A Frenzy: Mizuho Strategist on Playing the Pharma Deal Market

Merck's Strategic Acquisition of Sequerda Therapeutics

• 💡 Merck acquired Sequerda Therapeutics for $9.2 billion to bolster its pipeline ahead of the 2028 patent expiry of its key cancer drug, Keytruda.
• 🎯 The deal, which saw Sequerda's shares more than double, is seen as a strategic move to address Merck's future revenue needs.
• 💰 While some questioned if Merck overpaid, the acquisition price was reportedly in the 4-5 times revenue range, aligning with recent industry deals and suggesting multiple bidders were involved.

The Urgency of Patent Cliffs in Big Pharma

• ⚠️ Many large pharmaceutical companies, including Bristol Myers Squibb, Amgen, and Sanofi, face significant patent expirations in the coming years, creating urgency for pipeline replenishment.
• 🚀 Merck's strategy, including the Sequerda deal, Acceleron, and Verona, is viewed as a proactive approach to supplement Keytruda's declining revenue.
• 📈 The current M&A activity is expected to make 2026 one of the busiest years on record for deal volume, if not necessarily dollar value.

Biotech Sector Performance and Investment Strategy

• ⚡ The biotech sector has been exceptionally active since the summer, with numerous deals occurring across various companies like Novo Nordisk, Pfizer, and Lundbeck.
• 🔍 Investors are actively trying to identify the next potential acquisition targets amidst this M&A fervor.
• ✅ The overall healthcare sector, excluding biotech, is still viewed with caution due to lingering risks, despite recent underperformance narrowing.

Playing the Biotech M&A Trend

• 🌟 For investors who believe the M&A trend will continue, small and midcap biotech companies are identified as the prime area to invest.
• 🧩 The healthcare sector is complex, encompassing diverse industries like managed care, medical devices, and pharmaceuticals, making a blanket call difficult.
• 📈 However, if the pace of M&A continues, the recommendation is to be long biotech heading into the next year.